RERX THERAPEUTICS, INC

Biotech · Private

Small molecule therapeutic (ReRx-001) for obesity and metabolic disorders including diabetes, dyslipidemia, and fatty liver disease

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$752K
Grants
$752K
1 award
At sector median 1 award
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
At sector median 2 patents

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history, newest first
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Evaluation of novel small molecule targeting lipid and energy homeostasis for treating obesity$752,158
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1082Forward Therapeutics——
1083BIOHELIX CORPORATION——
1084LAMASSU BIO INC——
1085RERX THERAPEUTICS, INC——
1086MOLECULAR INTELLIGENCE LLC——
1087ENVISBIO LLC——
1088Chimera BioTechnology, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

No people are linked to this company yet.

People appear here when they are named as related persons in the company's own Form D filings. We don't infer people from social profiles.

Checked: SEC EDGAR Form D related persons through

Patents

USPTO · 0 granted of 2
  • Crystalline Forms Of 5-(TETRADECYLOXY)FURAN-2-CARBOXYLIC Acid And Salts Thereofapplication
  • Crystalline Forms of 5-(Tetradecyloxy)Furan-2-Carboxlyic Acid and Salts Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.